Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for VAP-1/AOC3 Antibody (393112) [Unconjugated]
amine oxidase, copper containing 3 (vascular adhesion protein 1)
Copper amine oxidase
Semicarbazide-sensitive amine oxidase
VAP-1membrane primary amine oxidase
Vascular adhesion protein 1
Vascular adhesion protein-1 (VAP-1), also called AOC3 (amine oxidase copper-containing 3) or SSAO (semicarbazide-sensitive amine oxidase), is a copper amine oxidase with a topaquinone cofactor. VAP-1 is a Type II integral membrane protein, but a soluble form of the enzyme is present in human serum, and its level increases in diabetes and some inflammatory liver diseases (1, 2). Human and mouse VAP-1 share 83% amino acid sequence identity. VAP-1 catalyzes the oxidative deamination of small primary amines such as methylamine, benzylamine, and aminoacetone in a reaction that produces an aldehyde, ammonia, and H2O2 (3). The enzyme is sensitive to inhibition by semicarbazide. VAP-1 expression is highest in the endothelium of lung, heart, and intestine, but low in tissues such as brain, spleen, kidney, and liver (4). VAP-1 vascular expression is regulated at sites of inflammation through its release from intracellular granules in which the protein is stored (5). The adhesive function of VAP-1 has been demonstrated in studies showing that the protein is important for the adherence of certain lymphocyte subtypes to inflamed endothelial tissues (6). VAP-1 mediated adhesion is involved in the process of leukocyte extravasation, an important feature of inflammatory responses. The role of VAP-1 amine oxidase activity in this process is not fully defined, but it appears to be carbohydrate-dependent (7). VAP-1 is considered to be a therapeutic target for diabetes, oxidative stress, and inflammatory diseases (8).
Kurkijärvi, R. et al. (1998) J. Immunol. 161:1549.
Gearing, A.J.H. and W. Newman (1993) Immunol. Today 14:506.
Lizcano, J.M. et al. (1998) Biochem. J. 331:69.
Smith, D.J. et al. (1998) J. Exp. Med. 188:17.
Jaakkala K. et al. (2000) Am. J. Pathol. 157:463.
Salmi, M. and J. Jalkanen (2001) Trends Immunol. 22:211.
Salmi, M. and J. Jalkanen (1996) J. Exp. Med. 183:569.
Dunkel, P. et al. (2008) Curr. Med. Chem. 15:1827.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our VAP-1/AOC3 Antibody (393112) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.